The primary use of Havrix 1440 is to help with establishing long-term immunity against the Hepatitis A Virus (HAV) infection. This therapeutic goal is applied across domains where additional symptomatic support is needed, including various therapeutic indications.

The immunization is considered relevant for managing risk in defined, high-prevalence scenarios, such as before international travel or during a community outbreak. This prophylactic measure assists with the prevention of pronounced symptoms, which are often related to systemic imbalance and significant physical discomfort, including fever, fatigue, nausea, and jaundice.

Havrix 1440 is relevant for conditions presenting with acute episodes and is commonly used across patient groups who face an increased risk of exposure. This includes adults with chronic liver diseases or those in specific high-exposure occupations. Immunization supports protection against significant symptomatic burden, assisting with maintaining functional stability, and contributes to improved day-to-day comfort. This benefit may assist with helping patients cope more steadily with symptom fluctuations associated with risk scenarios.

---

Quick Fact: Easing the Symptom Load The primary patient benefit provides support against the full spectrum of acute Hepatitis A symptoms, including the symptomatic physical discomfort and the potential for functional stress linked to organ-specific functional stress.

---

Who can and cannot use Havrix 1440?

This section outlines the official population eligibility and non-eligibility for Havrix 1440, based strictly on government regulatory documents.

---

Contraindications and Restrictions

Classification	Eligible Population	Non-Eligible Population
Age Eligibility	Individuals 16 years of age and above (19 years and older in the US)	Children under 1 year of age (use not established); Individuals below adult threshold for 1440 EL.U. dose.
Contraindications	Standard adult population	Individuals with known hypersensitivity to the active substance or excipients like neomycin or formaldehyde.
Conditional Use	Individuals with underlying conditions	Those with an acute severe febrile illness (use must be postponed).

---

Special Population Considerations

• Immunocompromised Status: Use is limited as the expected antibody response may be impaired in individuals whose immune system is compromised by disease or immunosuppressant therapy.
• Bleeding Disorders: Administration requires caution in patients with thrombocytopenia or a bleeding disorder due to the risk of bleeding from intramuscular injection.
• Pregnancy and Lactation: Use during pregnancy and breastfeeding is conditional, permitted only when clearly needed, due to limited clinical data in these populations. The safety profile is not established for use in the elderly population.

Interactions with other medicines and products

Regulatory documentation for Havrix 1440 (Hepatitis A Vaccine, Inactivated) primarily addresses pharmacodynamic effects on the immune system and mandatory constraints on co-administration, rather than typical pharmacokinetic (metabolic) interactions.

Documented Pharmacodynamic Interactions

Co-administration with immunosuppressive therapies results in a diminished immune response to the vaccine. Medicines and treatments classified as immunosuppressive, such as irradiation, antimetabolites, alkylating agents, and cytotoxic drugs, may reduce the body's ability to produce sufficient protective antibodies. This outcome is also noted as a population-specific consideration for individuals with impaired immune systems or those undergoing haemodialysis.

Administration-Related Constraints

Official labeling sets strict rules regarding the physical mixing and administration site for the product:

• Contraindicated Mixing: The vaccine is prohibited from being mixed with any other vaccine or product in the same syringe or vial prior to injection.
• Co-administration Method: When co-administered with other inactivated vaccines (such as Typhoid or Tetanus) or with Immune Globulin, all agents must be given using different syringes, needles, and injection sites. The simultaneous administration of these products is otherwise generally documented as unlikely to cause interference with the vaccine's protective effect.

Havrix 1440 is an inactivated viral particle preparation targeting the host immune system, specifically antigen-presenting cells (APCs) such as dendritic cells and macrophages. Following intramuscular administration, the viral antigens are endocytosed by APCs in the draining lymph nodes.

Within the APCs, the viral capsid proteins are processed into peptide fragments and subsequently loaded onto major histocompatibility complex (MHC) class II molecules. These MHC-peptide complexes are then translocated to the cell surface, initiating the molecular pathway of T-cell activation. The presentation of antigen to CD4+ T-helper cells triggers co-stimulatory signaling, leading to the clonal expansion and differentiation of antigen-specific T-helper cells.

This cellular cascade culminates in the activation of B-lymphocytes, which recognize the intact viral surface antigens. The T-helper cell signals promote the differentiation of these B-lymphocytes into plasma cells. Plasma cells are specialized biological effectors that synthesize and secrete large quantities of immunoglobulin G (IgG) antibodies into the systemic circulation. This systemic-level physiological modulation establishes a circulating antibody repertoire that binds selectively to the target viral particles, providing humoral immunological recognition.

Administration Instructions for Havrix 1440

The adult-strength formulation of Havrix 1440 (1440 ELISA units per 1.0 mL) is indicated for use in individuals typically 16 years of age and older or 19 years of age and older.

---

Preparation and Route of Administration

Preparation: The vaccine is a suspension for injection and must be shaken well before use to obtain a homogeneous, turbid, white suspension. The product should be visually inspected for discoloration or particulate matter prior to administration, and must not be used if either is present.

Route: Havrix 1440 is administered by intramuscular (IM) injection only. It must not be given into a vein (intravascularly), under the skin (subcutaneously), or into the skin (intradermally), as these routes may result in a less than optimal immune response.

Injection Site: In adults, the injection must be administered into the deltoid region (muscle of the upper arm). It should not be administered in the gluteal (buttock) region.

---

Dosing and Schedule

Primary Immunization: Primary vaccination consists of a single 1.0 mL dose. The primary dose should be administered at least two weeks prior to expected exposure.

Booster Dose: To ensure long-term protection, a booster dose of 1.0 mL is recommended. This booster should preferably be administered 6 to 12 months after the primary dose. If a dose is missed, a healthcare provider should be consulted to arrange another visit as soon as possible.

Concomitant Use: When co-administering with other injectable vaccines or human immunoglobulin (IG), the products must be given with different syringes and needles at separate injection sites.

Recent Clinical Evidence Overview

Havrix 1440 is an inactivated hepatitis A virus (HAV) vaccine indicated for active immunization against HAV infection in adults 19 years of age and older. Clinical research focuses primarily on the vaccine's ability to induce an immune response (immunogenicity), the duration of protection, and its safety profile.

---

Seroconversion and Onset of Response

Studies in healthy adults have demonstrated a rapid immune response following the first dose. Seroconversion (the development of protective anti-HAV antibodies) was observed in approximately 79% of subjects by day 15 and in 99% of subjects by one month after the primary 1.0 mL dose (1440 ELISA Units). This rapid onset of antibody production is generally shorter than the average incubation period of the hepatitis A virus.

---

Long-Term Persistence of Antibodies

Long-term follow-up studies confirm the persistence of anti-HAV antibodies after the recommended two-dose primary course (with the second dose typically given 6 to 12 months after the first). Data available after 17 years suggest that a large majority of subjects will remain seropositive for at least 30 years after the full two-dose regimen. Mathematical modeling extrapolates this persistence to 40 years for most subjects, although ongoing measurement is required to confirm these long-term projections.

---

Safety and Tolerability

Clinical trials involving thousands of subjects have reported that the vaccine is generally well-tolerated. The frequency of adverse events tends to decrease with successive doses.

Common Local Reactions	Common Systemic Reactions
Soreness at the injection site	Headache
Redness	Fatigue
Swelling or induration	Fever (37.5 C)

Most reported reactions are considered mild, do not last longer than 24 hours, and resolve spontaneously. Serious adverse events are reported very rarely, with no causal relationship established between the vaccine and most post-marketing neurological reports.

Common questions about Havrix 1440 (FAQ)

Q: Does the vaccine contain live virus?

According to the official product information, Havrix 1440 does not contain a live virus. It is prepared using an inactivated (killed) Hepatitis A virus antigen. The process of inactivation renders the material non-infectious, meaning it is not capable of transmitting the disease.

Q: What should I do if the vaccine was accidentally frozen?

Official regulatory documents emphasize that Havrix 1440 must not be frozen. The vaccine is destroyed by freezing. If the product is suspected to have been frozen, regulatory guidelines indicate it should be discarded and not administered.

Q: What is the best way to determine if I need a Hepatitis A vaccine?

Official product information states the vaccine is indicated for active immunization against Hepatitis A infection. Eligibility is generally based on official public health recommendations concerning risk factors for infection.

Q: What kind of reaction should prompt an immediate call to the doctor?

Serious adverse reactions are reported extremely rarely. Should signs of a severe allergic reaction (anaphylaxis) occur, such as difficulty breathing, swelling of the face, tongue, or throat, or the sudden onset of hives, official advice is to seek emergency medical attention immediately.

Official Storage and Disposal Requirements

Mandatory Storage Conditions

Havrix 1440 must be stored in a refrigerator at a temperature between 2 C and 8 C (35 F and 46 F). The vaccine must be kept in its original packaging to protect it from light. It is critical not to freeze the vaccine, as freezing destroys the product, and it must be discarded if this occurs. Always inspect the vaccine prior to use to ensure it is a homogeneous, white suspension.

Handling and Disposal

Keep the vaccine out of the reach and sight of children. Do not use the product after the expiration date printed on the label. Any unused or expired Havrix 1440 and related waste materials must be disposed of according to local regulatory requirements for medicinal products, and should not be placed in household waste or wastewater.